Enanta Pharmaceuticals (ENTA) Upgraded at BidaskClub

Enanta Pharmaceuticals (NASDAQ:ENTA) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Tuesday.

A number of other analysts have also recently commented on ENTA. Zacks Investment Research raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $87.00 price target on the stock in a research report on Tuesday, October 9th. ValuEngine cut Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 8th. Oppenheimer set a $100.00 price target on Enanta Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, November 27th. TheStreet cut Enanta Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Monday, November 26th. Finally, Berenberg Bank began coverage on Enanta Pharmaceuticals in a research report on Thursday, December 13th. They issued a “hold” rating and a $80.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company’s stock. Enanta Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $100.00.

Shares of ENTA traded up $0.33 during mid-day trading on Tuesday, reaching $72.28. The company had a trading volume of 248,934 shares, compared to its average volume of 245,127. Enanta Pharmaceuticals has a 52 week low of $52.39 and a 52 week high of $127.77. The stock has a market cap of $1.43 billion, a P/E ratio of 20.77 and a beta of 0.91.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, November 26th. The biotechnology company reported $1.30 EPS for the quarter, topping analysts’ consensus estimates of $1.24 by $0.06. Enanta Pharmaceuticals had a return on equity of 21.56% and a net margin of 34.82%. The firm had revenue of $67.20 million for the quarter, compared to analysts’ expectations of $69.03 million. During the same period in the previous year, the firm posted $1.86 EPS. The business’s revenue for the quarter was down 11.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Enanta Pharmaceuticals will post 1.7 EPS for the current fiscal year.

In related news, insider Tim Ocain sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $83.64, for a total value of $2,091,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Nathalie Adda sold 4,155 shares of the company’s stock in a transaction that occurred on Thursday, September 20th. The shares were sold at an average price of $95.32, for a total value of $396,054.60. Following the completion of the transaction, the vice president now directly owns 4,155 shares in the company, valued at $396,054.60. The disclosure for this sale can be found here. Corporate insiders own 10.56% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its holdings in shares of Enanta Pharmaceuticals by 2.9% during the 2nd quarter. BlackRock Inc. now owns 2,433,000 shares of the biotechnology company’s stock valued at $281,985,000 after buying an additional 68,564 shares during the period. Rhumbline Advisers lifted its holdings in shares of Enanta Pharmaceuticals by 1.9% during the 2nd quarter. Rhumbline Advisers now owns 37,550 shares of the biotechnology company’s stock valued at $4,352,000 after buying an additional 691 shares during the period. ClariVest Asset Management LLC lifted its holdings in shares of Enanta Pharmaceuticals by 98.7% during the 2nd quarter. ClariVest Asset Management LLC now owns 21,661 shares of the biotechnology company’s stock valued at $2,510,000 after buying an additional 10,761 shares during the period. Summit Global Investments bought a new position in shares of Enanta Pharmaceuticals during the 2nd quarter valued at $707,000. Finally, HL Financial Services LLC bought a new position in shares of Enanta Pharmaceuticals during the 3rd quarter valued at $3,870,000. 84.94% of the stock is currently owned by institutional investors and hedge funds.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.

Featured Story: What are trading strategies for the 52-week high/low?

Analyst Recommendations for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit